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Background: Inhaled glucocorticosteroids reduce airway inflammation in asthma patients,
thereby improving lung function and reducing airway hyperresponsiveness and symptoms.
The response to glucocorticosteroids can be measured with the glucocorticosteroid skin-
blanching test. We investigated if asthmatics have a lower skin-blanching response to glucocor-
ticosteroids than non-asthmatic subjects and if asthmatics with airway obstruction have lower
skin-blanching response than those without obstruction. Finally, we assessed which clinical and
inflammatory parameters influence the variability in skin-blanching response.
Methods: We evaluated the skin-blanching response to topical budesonide in a large group of
315 well-characterized asthmatics and their relatives (asthma n Z 114, healthy n Z 140,
other Z 61)
Results: The skin-blanching scores of the asthma probands and their healthy spouses were not
significantly different. The skin-blanching score of patients with FEV1 < 80% predicted was
lower than of patients without obstruction. Lower skin-blanching score was significantlyry volume in 1 s; AMP, adenosine-5-monophosphate; MRC, Medical Research Council; IgE, immuno-
ration causing a 20% fall in FEV1; PD20, provocative cumulative dose causing a 20% fall in FEV1; OCT3,
ocorticoid receptor; GRE, glucocorticosteroid responsive element.
0 361 4215; fax: þ31 50 361 4235.
cg.nl (E.D. Telenga), m.van.den.berge@umcg.nl (M. van den Berge), j.m.vonk@umcg.nl (J.M. Vonk),
ie_lange@med.unc.edu (L.A. Lange), d.s.postma@umcg.nl (D.S. Postma), g.h.koppelman@umcg.nl
Copyright ª 2012 Published by Elsevier Ltd. All rights reserved.
12.06.007
Skin-blanching is associated with FEV1 and allergy 1377associated with lower FEV1 %predicted, higher age, female gender, absence of allergy and
summer season, but not with use of inhaled or oral glucocorticosteroids or packyears smoking.
Conclusions: Asthmatics do not have lower skin-blanching response to glucocorticosteroids
than healthy subjects. Furthermore, lower skin-blanching response to glucocorticosteroids is
associated with lower FEV1, female gender, higher age and the absence of allergy.
Crown Copyright ª 2012 Published by Elsevier Ltd. All rights reserved.Introduction
Asthma is a common respiratory disease, characterized by
airwayhyperresponsiveness andaccompaniedby intermittent
airway obstruction and respiratory symptoms. The underlying
inflammatory process in asthma is effectively treated by
inhaled glucocorticosteroids.1e3 However, a subset of asthma
patients has a reduced response to glucocorticosteroids. This
reduced response can lead to worse asthma control and lower
lung function. There are even patients who are completely
resistant to glucocorticosteroids. These patients account for
a large percentage of the burden of asthma morbidity, which
greatly increases health care costs.4
A way to test for responsiveness to glucocorticosteroids
is the glucocorticosteroid skin-blanching test, also known as
the McKenzie skin-blanching test.5 Thus far, only two
studies have compared skin-blanching response of asthma
patients to healthy controls and their results have been
conflicting. In the first study, asthma patients had a lower
skin-blanching response than healthy controls.6 In this
study, the asthma patients had marked airway obstruction
(mean FEV1 63% of predicted). In another study healthy
controls and asthma patients had similar skin-blanching
response.7 However, the latter study showed that
a subgroup of glucocorticosteroid resistant asthma patients
who had more severe airway obstruction demonstrated
reduced skin-blanching response. Taken together, it
remains unclear whether a lower skin-blanching response is
associated with the presence and severity of asthma.
There is considerable variability in glucocorticosteroid
response between individuals,8 and it is unclear which
variables determine the variation of the skin-blanching
response to glucocorticosteroids between individuals. In
this study we investigated the skin-blanching response in
patients with asthma (probands) and their families. Our
primary research question was whether asthma patients
have a lower skin-blanching response to glucocorticoste-
roids than non-asthmatic subjects. Secondary, we investi-
gated if asthma patients with airway obstruction have
a lower skin-blanching response than asthma patients
without airway obstruction and, which clinical and inflam-
matory parameters are associated with the variability in
skin-blanching response.Methods and materials
Study population
Between 1962 and 1975, asthma patient in adolescence or
early adulthood were admitted to a local asthma referralcenter.9 From this population, asthma patients were
included, based on the following criteria: age <45 years,
bronchial hyperresponsiveness to histamine and clinical
symptoms of asthma according to current criteria of the
American Thoracic Society. This cohort of asthma patients,
also called probands, has been followed for 25e30 years
and participated with their family members (spouse, chil-
dren, children’s spouses and grandchildren) in a family
study on the genetics of asthma between 1991 and 1994.
The first 93 families (nZ 499) were asked to participate in
a second evaluation between 1997 and 1999, which
included the glucocorticosteroid skin-blanching test. The
Medical Ethics Committee of the University Hospital Gro-
ningen approved the study; all participants provided
written informed consent. For subjects <18 years written
informed consent was provided by a parent/guardian.
Clinical evaluation
Phenotyping protocol family visit 1991e1994
Data on respiratory symptoms, allergic status, use of (glu-
cocorticosteroid) medication and smoking were obtained by
a modified version of the British Medical Research Council
(MRC) questionnaire.10 For children younger than 16 years
of age, the mother was asked to complete an extended
respiratory symptom questionnaire. The forced expiratory
volume in 1 s (FEV1) was measured using a water-sealed
spirometer (Lode Spirograph type DL, Lode b.v., Gronin-
gen, The Netherlands). A subject was considered hyperre-
sponsive to histamine if the provocative concentration
producing a 20% fall (PC20 histamine) in FEV1 was 32 mg/
mL. In subjects older than 12 years intracutaneous tests
with 16 common aeroallergens were performed. In children
younger than 12 years, a skin prick test was performed with
10 allergens. Subjects with at least one positive skin test
were considered to be allergic.
Phenotyping protocol second family visit 1997e1999
During the second family visit, questionnaires and spirom-
etry were performed as described above. Additional phe-
notyping included the glucocorticosteroid skin-blanching
test, measurements of blood eosinophils, blood cortisol and
Immunoglobulin E (IgE) (enzyme-linked fluorescence assay,
Mini Vidas, Biomerieux) and bronchial hyperresponsiveness
to adenosine-5-monophosphate (AMP). A subject was
considered hyperresponsive to AMP if the cumulative
provocative dosage producing a 20% fall (PD20 AMP) in FEV1
was 32 mg. The glucocorticosteroid skin-blanching test
was performed by application of budesonide on the skin of
the volar side of the forearm using a protocol adapted from
Brown et al.7 Briefly, budesonide was dissolved in 96%
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(0.3, 1, 3.3, 10, 33.3, 100, 333, 1000 mg/mL). Test sites of
2 cm diameter were outlined by double-sided adhesive
tape. The eight test concentrations of budesonide were
randomly applied to the skin, 10 mL to each site. After
evaporation of the diluent, the sites were covered with
a plastic film. After 6 h of exposure the plastic film and
adhesive tape were removed. The degree of skin-blanching
was assessed 1 h later after resolution of any tape-related
erythema. The skin-blanching score was assessed under
standard lighting conditions (with no natural light) by
trained observers, blinded to the distribution of concen-
trations. Blanching was graded according to a 7-point scale,
varying from 0 (no blanching), 0.5, 1, 1.5, 2, 2.5 to 3
(intense blanching).11 A pilot experiment showed high
agreement between observers (weighted Kappa Z 0.88,
Fleiss Cohen).
Statistical methods
The presence of asthma was based on an algorithm as
described previously,9 which incorporates bronchial
hyperresponsiveness to histamine, respiratory symptoms
(MRC questionnaire), smoking, airway obstruction and
bronchodilator response. Subjects were divided into three
categories: ‘asthma’, ‘healthy’ (no clinical evidence of
asthma or COPD) and ‘other’ (COPD or unclassifiable airway
disease). We used the skin-blanching score to assess the
skin-blanching response. This score was calculated as the
mean skin-blanching score over the total of all concentra-
tions. To approximate a normal distribution, the mean skin-
blanching score was log-transformed. To test for differ-
ences in skin-blanching between asthma patients and
healthy subjects, we compared the skin-blanching score of
asthma probands and their healthy spouses with Student’s
T-test. We used only the probands and their spouses for this
analysis, since these groups are genetically independent.
Sample size calculations were based on the findings of
Livingston and colleagues.6 To detect a difference of 0.26 in
the mean blanching score between probands and healthy
spouses, with a standard deviation of 0.36, an alpha of 0.05
and beta of 0.9, we needed 40 subjects per group. To test
which clinical and cellular variables were associated with
the skin-blanching response, we performed a regression
analysis for skin-blanching score. All regression analyses
were performed using linear mixed models, with family as
random factor. This method corrects for a possible depen-
dency between subjects from the same family. First we
examined univariate models. The pool of variables was
chosen based on available literature. Variables with a p-
value of 0.10 or less in the univariate model were entered
into the multivariate analysis. Age, gender, smoking and
asthma status were included in the multivariate model
irrespective of the results of the univariate analyses. All
analyses were performed using SPSS statistical software
version 16.
Results
Members of 71 out of 93 invited families were willing to
participate. These 71 families consisted of 329 individuals:66 probands, 67 spouses, 165 children, 12 children’s spou-
ses and 19 grandchildren. The results from the skin-
blanching test were available for analysis in 315 of the
329 participating subjects. It was not possible to classify
one subject because of a missing bronchial hyper-
responsiveness measurement. Of the 314 remaining
subjects, 114 were classified as ‘asthma’, 140 as ‘healthy’
(no asthma or COPD) and 60 as ‘other’ (10 COPD and 50
unclassifiable). The clinical characteristics of the 315
participating individuals are outlined in Table 1.
Skin-blanching response of asthma probands and
healthy spouses
The skin-blanching scores of asthma probands and healthy
spouses were not significantly different (pZ 0.675, Fig. 1).
However, the skin-blanching score of asthma probands with
airway obstruction (FEV1 <80% predicted) was lower than
the skin-blanching score of asthma probands without
obstruction (p  0.001, Fig. 2). Probands with airway
obstruction more often used glucocorticosteroids than
probands without airway obstruction (23/32 vs. 7/31) and
they were older (58 vs. 53 years) and less often allergic (23/
31 vs. 30/31). Therefore, we performed regression analysis
to assess which variables are associated with the skin-
blanching response. Moreover, the skin-blanching response
to corticosteroid was not associated with decline in FEV1 in
44 patients with sufficient data available (data not shown).
Predictors of skin-blanching response
In the univariate analysis of all 315 subjects a lower skin-
blanching score was associated with lower FEV1, older age,
absence of allergy, the use of glucocorticosteroids, more
packyears smoked and a skin-blanching test performed in
summer or fall (Table 2). The skin-blanching score was not
associated with gender, asthma status, bronchial hyper-
responsiveness to AMP, total IgE, blood eosinophil number,
cortisol, symptoms, or observer scoring the result. In the
multivariate analysis (308 subjects) a lower skin-blanching
score was independently associated with lower FEV1
(p Z 0.012), older age (p < 0.001), female gender
(p Z 0.047), absence of allergy (p Z 0.0019) and a skin-
blanching test performed in summer rather than winter
(p Z 0.047, Table 3).
Discussion
In this study, we provide evidence that patients with asthma
do not have a lower skin-blanching response to glucocorti-
costeroids than non-asthmatic subjects. This is based on the
observation that asthma probands and their healthy spouses
had a similar skin-blanching score (Fig. 1). In addition, in our
multivariate analysis asthma status was not associated with
the skin-blanching score. Skin-blanching response does
appear to be associated with level of airway obstruction,
since probands with an FEV1 <80% predicted (n Z 33) had
lower skin-blanching scores than probands with normal lung
function (nZ 31). Furthermore, lower skin-blanching score
was significantly associated with lower FEV1 in the complete
study population. The other main finding of this study is that
Table 1 Subject characteristics.
All N Z 315 Asthma N Z 114 Healthyc N Z 140
Age, yrs 41 (15) 46 (16) 39 (14)
Male, n (%) 164 (52) 66 (58) 73 (52)
Mean skin-blanching score 0.8 (0.5) 0.8 (0.5) 0.8 (0.4)
Never-smokers, n (%) 133 (42) 49 (43) 59 (42
Ex-smokers, n (%) 70 (22) 31 (27) 25 (18)
Current-smokers, n (%) 111 (35) 34 (29) 55 (40)
Packyears 6.1 (9.8) 6.8 (12.2) 5.8 (8.5)
Use of glucocorticosteroids, n (%) 42 (13) 41 (35) 1 (0.7)
ICS only 37 (11) 36 (31) 1 (0.7)
ICS and oral corticosteroids 4 (1) 4 (3) 0
Oral corticosteroids only 1 (0.3) 1 (0.8) 0
Total IgE, kU/La 47 (0e6120) 88 (4e6120) 27 (0e1500)
Blood eosinophils, 107/La 9 (1e121) 12 (1e121) 8 (1e61)
Blood cortisol, nmol/La 467 (38e1160) 437 (38e1121) 479 (209e1160)
Allergyb n (%) 161 (51) 94 (83) 40 (29)
PD20 AMP 32 mg, n (%) 89 (31) 60 (64) 13 (9)
FEV1 %predicted 96 (20) 83 (24) 105 (12)
Values are in means (SD).
a Geometric mean (range), or number (%); FEV1 Z forced expiratory volume in 1 s.
b 1 positive skin test; PD20 AMP Z Cumulative dose of adenosine-5-monophosphate provoking a 20% decrease in FEV1.
c No clinical evidence of asthma or COPD.
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associated with age, gender, allergy and season. Impor-
tantly, the skin-blanching score was not associated with the
use of glucocorticosteroids and smoking. Although the
precise mechanisms of action of the glucocorticosteroid
skin-blanching test are unknown, it provides an easy, direct
assessment of glucocorticosteroid sensitivity, making it an
interesting test for investigating glucocorticosteroid sensi-
tivity in asthma.
The similar skin-blanching response of asthma patients
and healthy subjects is consistent with a previous study,7
comparing steroid-sensitive asthma patients and controls.
However, it contrasts with another study in 75 asthma
patients and 78 healthy controls. In this study, skin-
blanching response to glucocorticosteroids was lower in
asthma patients than in healthy controls.6 However, those
asthmatics had marked airway obstruction (mean FEV1 63%
of predicted) and this may have influenced the results,
which fits with our observation that asthma probands with
more severe airway obstruction (FEV1<80% predicted) had
a lower skin-blanching response. Additionally, multivariate
analysis revealed that a lower skin-blanching response was
associated with lower FEV1. These results suggest that,
although skin-blanching response is similar in asthma
patients in general and in non-asthmatic controls, it may be
reduced in a subgroup of older patients who have non-
allergic asthma and airway obstruction.
It is tempting to speculate that the airway obstruction in
the subgroup of older non-allergic asthma patients with
reduced skin-blanching response is associated with a lower
treatment response to inhaled glucocorticosteroids, thus
translating the response in the skin to the airways.
However, this speculation is not supported by the results of
a study in 22 patients with mild-to-moderate asthma.11 In
this study, the skin-blanching response to glucocorticoste-
roids was not associated with changes in serum cortisol orbronchial hyperresponsiveness after a 3-week treatment
with inhaled glucocorticosteroids. However, the results of
this study do not rule out an effect of lower treatment
response either, since included patients may have had
asthma of too mild severity (mean FEV1 was 86% predicted)
to show differences in treatment response. FeNO and
sputum eosinophils are validated markers of airway
inflammation which can be used for assessing the response
to anti-inflammatory therapy in patients with asthma12,13
and novel non-invasive markers of airway inflammation
are being characterized.14 Future prospective studies to
establish the relationships between skin-blanching
response to glucocorticosteroids and lung inflammatory
parameters should be undertaken.
Skin-blanching after topical application of glucocorti-
costeroids, is caused by sub-dermal vasoconstriction. The
mechanisms of this effect may include both non-genomic
(i.e. direct inhibitory effects) and genomic (i.e. transcrip-
tional) effects through binding of the glucocorticosteroid
receptor. Studies in rabbit models have provided insight
into non-genomic mechanisms of glucocorticosteroid action
on vasoconstriction.15,16 One of these mechanisms is via
inhibitory effects on the enzyme organic cation transporter
3 (OCT3).17 Inhibition of OCT3 by glucocorticosteroids
increases noradrenalin at the a1-adrenergic receptor, which
then causes vasoconstriction. The rapid onset of the vaso-
constrictive effect of inhaled glucocorticosteroids in the
lung (i.e. 30 min) is consistent with a direct, non-genomic,
effect.18 However, the maximum effect 8e12 h after
application and the duration of the vasoconstrictive effect
(>24 h) suggests that additional mechanisms, like genomic
effects, are likely important.19,20 The genomic mechanisms
may be binding to the glucocorticoid receptor (GR) and
regulation of genes with glucocorticosteroid responsive
elements (GRE’s) or recruitment of histone deacetylase.21
An indication that regulation of genes with a GRE may be
Figure 2 Skin-blanching score in asthma probands with and
without obstruction. FEV1 Z forced expiratory volume in 1 s.
Boxplot showing skin-blanching score in asthma probands and
healthy spouses.
Figure 1 Skin-blanching score in asthma probands and
healthy spouses. FEV1 Z forced expiratory volume in 1 s;
ns Z not statistically significant. Boxplot showing skin-
blanching score in asthma probands and healthy spouses.
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showed a putative GRE in the promoter region of the OCT3
gene (Huge gene name: Solute carrier 22, member 3,
SLC22A3).22 Further evidence for a role of GR’s in skin-
blanching response to glucocorticosteroids, was provided
by a study of skin-blanching response in healthy volunteers
with different genetic variants of the glucocorticosteroid
receptor gene. A BclI restriction fragment length poly-
morphism (AA genotype) of the GR gene was associated
with an increased skin-blanching response to glucocorti-
costeroids.23 Finally, inhibition of the GR by a pharmaco-
logical inhibitor resulted in decreased skin-blanching
response in healthy subjects, supporting the role of GR’s in
the skin-blanching response.24 We found an increased skin-
blanching response to glucocorticosteroids in individuals
with positive skin tests to allergens, but not with elevated
blood eosinophils or total serum IgE levels. This observation
was surprising since asthma patients with higher levels of
eosinophils or IgE have been reported to have a better
glucocorticosteroid response.25,26 The mechanism of
increased skin-blanching response in allergic subjects is
unknown. OCT3, which is likely to be involved in the skin-blanching response, may also play a role in allergy by
impaired histamine clearance, since OCT3 is a transporter
of histamine in rats.17 Furthermore, OCT3 mRNA was down-
regulated in a rabbit model of ovalbumin-induced allergic
sensitization.15
In this study, several parameters were associated with
the skin-blanching response to glucocorticosteroids. First,
lower skin-blanching response was associated with
increasing age. Little is known about glucocorticosteroid
sensitivity and age. In one study, peripheral whole blood of
older men showed less inhibition by dexamethasone of IL-6
production after stimulation with lipopolysaccharide than
blood of younger men, which represents lower glucocorti-
coid sensitivity.27 Another study showed that the number of
GR’s in the hypothalamus decreases with increasing age.28
However, it is not known if a similar effect is present in
skin tissue. These and our studies suggest that with
increasing age, glucocorticoid sensitivity decreases,
however this has yet to be confirmed. Second, lower skin-
blanching response was associated with lower lung func-
tion. No prior studies have described a relationship
between glucocorticosteroid responsiveness and lung
Table 3 Multivariate analysis with skin-blanching score
(log transformed) as outcome variable.
Variable Multivariate
b SE p-value
Age, per 10 years 0.047 0.011 <0.001
Gender (male vs. female) 0.055 0.028 0.047
Use of glucocorticosteroids 0.007 0.053 0.897
FEV1 %predicted, per 10% 0.024 0.009 0.012
Allergya 0.083 0.032 0.010
Packyears 0.001 0.002 0.406
Season
Spring vs. winter 0.005 0.055 0.924
Summer vs. winter 0.112 0.056 0.047
Fall vs. winter 0.062 0.056 0.276
Asthma status
Asthma vs. healthy 0.011 0.045 0.810
Unclassifiable vs. healthy 0.032 0.038 0.394
bZ regression coefficient; SEZ standard error; FEV1Z forced
expiratory volume in 1 s.
Bold values represent the significant p values (<0.05).
a 1 positive skin test; Winter Z DecembereFebruary;
Spring Z MarcheMay; Summer Z JuneeAugust;
Fall Z SeptembereNovember.
Table 2 Univariate analysis with skin-blanching score (log
transformed) as outcome variable.
Variable N Z 315
Univariate
b SE p-value
Age, per 10 years 0.061 0.009 <0.001




FEV1 %predicted, per 10% 0.029 0.007 <0.001
Allergya 0.078 0.030 0.010
Packyears 0.006 0.006 <0.001
Season
Spring vs. winter 0.054 0.060 0.368
Summer vs. winter 0.166 0.061 0.007
Fall vs. winter 0.138 0.061 0.025
PD20 AMP 32 mg 0.027 0.033 0.414
Total IgE (kU/L) 0.005 0.021 0.804
Blood eosinophils (107/L) 0.020 0.172 0.256
Blood cortisol (nmol/L) 0.130 0.086 0.131
Symptoms (MRC) 0.010 0.011 0.405
Observer
Observer 1 vs. 3 0.051 0.090 0.566
Observer 2 vs. 3 0.009 0.063 0.884
Asthma status
Asthma vs. healthy 0.058 0.041 0.164
Unclassifiable vs. healthy 0.035 0.040 0.379
bZ regression coefficient; SEZ standard error; FEV1Z forced
expiratory volume in 1 s.
Bold values represent significant p values (<0.05).
a 1 positive skin test; PD20 AMP Z Cumulative dose of
adenosine-5-monophosphate provoking a 20% decrease in FEV1;
Winter Z DecembereFebruary; Spring Z MarcheMay;
Summer Z JuneeAugust; Fall Z SeptembereNovember;
MRC Z Medical Research Council.
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association remains unclear. A possible explanation may be
that subjects with a lower response to endogenous gluco-
corticosteroids have either less lung growth or a more rapid
decline in lung function; however no data exists to support
this claim. Third, lower skin-blanching response was asso-
ciated with female gender. This finding is consistent with
a study in which skin-blanching was measured with laser
Doppler imaging and diffuse reflectance spectroscopy in
healthy volunteers.20 Gender differences were also found
in a study in which asthma patients were treated with
glucocorticosteroids. Treatment with inhaled corticoste-
roids significantly decreased the decline in FEV1 in male,
but not in female asthma patients.29 These findings suggest
that women have a reduced response to glucocorticoste-
roids. Female sex hormones may be involved in this reduced
responsiveness, since estrogen has pro-inflammatory30,31
and progesterone anti-inflammatory properties.32,33
Finally, we found that the skin-blanching response was
higher in winter compared to summer. This is in accordance
with another study, which found the same association in
healthy controls.34 A possible explanation for the increased
skin-blanching response is that vitamin D levels areincreased in summer. Higher levels of vitamin D have been
associated with increased glucocorticosteroid-response and
higher lung function.35 Another explanation may be that
differences in skin tanning influences the reading of the
test.
In conclusion, we have shown that asthma patients in
our study population do not have a lower skin-blanching
response to glucocorticosteroids than non-asthmatic
subjects. When interpreting results from skin-blanching
tests, the season should be taken into account, as the
skin-blanching response differs between seasons. Finally,
a lower skin-blanching response to glucocorticosteroids is
associated with lower FEV1, female gender, increased age
and the absence of allergy.
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